BBB Therapeutics (Netherlands)
We believe that we can transform the lives of those affected faster and more successful by combining known disease targets and compounds with established drug delivery systems united with safe targeting technology. This has led to two programs in clinical development for the treatment of brain cancer and neuro-inflammatory diseases. 2-BBB started as a spin-off company from the Blood-Brain Barrier Research Group of the Leiden Academic Center for Drug Research (LACDR) from Leiden University in the
Basic Information
- Category: business
- Website: http://www.bbbtherapeutics.com/
Documented Facts
- Email: info@2-bbb.com (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about BBB Therapeutics (Netherlands).
- Canonical profile: https://brandsource.ai/brands/bbb-therapeutics-netherlands
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/bbb-therapeutics-netherlands/json-ld
- Citation profile API: https://brandsource.ai/api/brands/bbb-therapeutics-netherlands/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We believe that we can transform the lives of those affected faster and more successful by combining known disease targets and compounds with established drug delivery systems united with safe targeting technology. This has led to two programs in clinical development for the treatment of brain cancer and neuro-inflammatory diseases. 2-BBB started as a spin-off company from the Blood-Brain Barrier Research Group of the Leiden Academic Center for Drug Research (LACDR) from Leiden University in the
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.